Biofrontera Q2 Revenue Jumps 15%

Biofrontera(NASDAQ:BFRI) reported fiscal second quarter results for the period ended June 30, 2025, with total revenues rising to $9 million from $7.8 million a year earlier, representing a 15% year-over-year increase. The company highlighted transformative progress toward operational independence, margin expansion, and late-stage clinical advances that could expand its addressable market. The following insights examine margin transformation, commercial execution, and long-term growth drivers for investors.Cost of revenues (GAAP) declined by 42% year-over-year in the fiscal second quarter, driven by a structural shift from a 25%-35% transfer price to a 12% royalty as part of the restructuring with Biofrontera AG. This change, effective for the 2025 fiscal year to date, materially improves unit economics as Ameluz volume reaches all-time highs and provides a buffer against potential tariff impacts as manufacturing transitions in-house.This cost structure evolution positions the company for sustainable gross margin improvement and enhances financial resilience by aligning royalties with realized U.S. revenues.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool